Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in
combination with palbociclib in patients with advanced solid tumor malignancies with KRAS
G12C mutation.